METHODS: We developed protocol for drug allergy testing that includes Basophil activation test (Reflab, Denmark), patch testing (AllergEase MS380 metronidazole, 1%, pet), skin prick testing in 1:100, 1:10 and maximum non-irritant concentration for skin testing 5 mg/mL, intradermal testing 1:1000; 1:100, 1:10 of maximum non-irritant concentration 2.5 mg/mL and oral allergen challenge test up to cumulative dose of 800mg given at 30 min intervals and observation of 2 hours for negative test or in case of positive result observation and treatment was determined clinically with an option of use of desensitisation protocol if required.
RESULTS: This protocol allows to reduce risks of severe reactions during testing starts with laboratory tests and patch tests that help to give information on both delayed and immediate response. This protocol is designed for use in ambulatory care as a day case admission in the hospital setting with all required emergency care available on standby.
CONCLUSIONS: This method is validated and is used routinely in clinical practice. London Allergy and Immunology Centre is a member of the European Network for Drug Allergy ENDA